<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Graves&#39; Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Graves&#39; Disease</span>
        </nav>

        <header class="page-header">
            <h1>Graves&#39; Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Endocrine Disorder</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0005364" target="_blank">
                        MONDO:0005364
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Thyroid Disorder</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">16</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autoantibody Production</div>
                
                <div class="item-desc">The immune system produces thyroid-stimulating immunoglobulins (TSIs) that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive thyroid.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000084" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">cAMP-mediated signaling</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37047805" target="_blank">PMID:37047805</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease is primarily mediated by B cells, which produce autoantibodies against the thyroid-stimulating hormone receptor (TSHR), chronically stimulating it and leading to high levels of thyroid hormones in the body."</div>
                
                
                <div class="evidence-explanation">The literature confirms the role of B cells in producing autoantibodies that stimulate the thyroid, but it does not explicitly mention thyroid-stimulating immunoglobulins (TSIs).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1356056" target="_blank">PMID:1356056</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"In the former, there is overactivity of the thyroid due to the action of a thyroid-stimulating antibody (TSAb)."</div>
                
                
                <div class="evidence-explanation">The literature confirms that thyroid-stimulating antibodies (TSAb) cause overactivity of the thyroid, but it does not explicitly mention T cells or the term &#39;thyroid-stimulating immunoglobulins (TSIs)&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6129186" target="_blank">PMID:6129186</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The presence of thyroid-stimulating immunoglobulins in patients with Graves&#39; disease is well established."</div>
                
                
                <div class="evidence-explanation">The literature confirms the presence of thyroid-stimulating immunoglobulins (TSIs) in Graves&#39; disease but does not explicitly mention the involvement of T cells.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Thyroid Overactivity</div>
                
                <div class="item-desc">Excessive stimulation of the thyroid gland results in increased production of thyroid hormones (thyroxine, T4, and triiodothyronine, T3).</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">thyroid hormone biosynthetic process</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/14654350" target="_blank">PMID:14654350</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In Graves&#39; disease, thyroid-stimulating autoantibodies can mimic TSH action and stimulate thyroid cells. This leads to hyperthyroidism and abnormal overproduction of thyroid hormone."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement that excessive stimulation of the thyroid gland in Graves&#39; Disease results in increased production of thyroid hormones (T4 and T3), leading to hyperthyroidism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17380820" target="_blank">PMID:17380820</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common causes are Graves&#39; disease, toxic multinodular goitre and toxic solitary nodule. Excess thyroid hormones in the circulation are also found in thyroiditis (hormone leakage) and excess exogenous thyroxine intake."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by listing Graves&#39; disease as a common cause of hyperthyroidism due to the increased production of thyroid hormones.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/9292944" target="_blank">PMID:9292944</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"BCGF production by T cells from the thyroid or peripheral blood of Graves&#39; patients, in the absence or presence of PHA, was significantly greater than that by peripheral T cells from healthy controls."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by indicating the role of immune cells in the thyroid gland&#39;s overactivity in Graves&#39; disease, contributing to the excessive production of thyroid hormones.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune System Dysregulation</div>
                
                <div class="item-desc">Dysregulated immune response leads to autoimmune attacks on the thyroid gland.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000084" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        T follicular helper cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0002038" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        CD4-positive, alpha-beta T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000624" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        regulatory T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000815" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">B cell activation</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37047805" target="_blank">PMID:37047805</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease is primarily mediated by B cells, which produce autoantibodies against the thyroid-stimulating hormone receptor (TSHR)... T cell populations are markedly distinct, including increased levels of Th17 and follicular helper T cells (Tfh), while Treg cells appear to be impaired."</div>
                
                
                <div class="evidence-explanation">This reference supports the involvement of both B cells and T cells in the dysregulated immune response leading to autoimmune attacks on the thyroid gland in Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37515444" target="_blank">PMID:37515444</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The incidence of autoimmune thyroid diseases, such as subacute thyroiditis, Graves&#39; disease, and Hashimoto&#39;s thyroiditis, increases in individuals with COVID-19 infection. This phenomenon may be attributed to aberrant responses of T-cell subtypes, the presence of autoantibodies, impaired..."</div>
                
                
                <div class="evidence-explanation">This reference supports the involvement of T cells and B cells (through autoantibodies) in the immune dysregulation associated with Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21850926" target="_blank">PMID:21850926</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The autoimmunity to the thyroid gland mainly consists of Hashimato thyroiditis and Grave&#39;s disease... The thyroid stimulating hormone receptor, thyroglobuline, enzymes of thyroid hormones synthesis are targeted by autoantibodies and cell- mediated reactions."</div>
                
                
                <div class="evidence-explanation">This reference supports the role of B cells (through autoantibodies) and T cells in the autoimmune attack on the thyroid gland in Graves&#39; disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts</div>
                
                <div class="item-desc">In thyroid eye disease, cooperative signaling between thyrotropin receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        fibroblast
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000057" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">cAMP-mediated signaling</span>
                    
                    <span class="tag tag-bio">MAPK cascade</span>
                    
                    <span class="tag tag-bio">phosphatidylinositol 3-kinase signaling</span>
                    
                    <span class="tag tag-bio">adipocyte differentiation</span>
                    
                    <span class="tag tag-bio">hyaluronan biosynthetic process</span>
                    
                    <span class="tag tag-bio">extracellular matrix organization</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Germinal Center Autoantibody Production</div>
                
                <div class="item-desc">CD40-CD40L interactions between T follicular helper cells and B cells drive germinal center formation and affinity maturation of TRAb-producing B cells with oligoclonal expansion and epitope spreading.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        B cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000236" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        T follicular helper cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0002038" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">B cell activation</span>
                    
                    <span class="tag tag-bio">adaptive immune response</span>
                    
                    <span class="tag tag-bio">germinal center formation</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Heat_Intolerance[&#34;Heat Intolerance&#34;]
    Sweating[&#34;Sweating&#34;]
    Hyperthyroidism[&#34;Hyperthyroidism&#34;]
    Weight_Loss[&#34;Weight Loss&#34;]
    Thyroid_Overactivity[&#34;Thyroid Overactivity&#34;]
    Increased_Appetite[&#34;Increased Appetite&#34;]

    Thyroid_Overactivity --&gt; Hyperthyroidism
    Hyperthyroidism --&gt; Weight_Loss
    Hyperthyroidism --&gt; Increased_Appetite
    Hyperthyroidism --&gt; Heat_Intolerance
    Hyperthyroidism --&gt; Sweating

    style Heat_Intolerance fill:#fef3c7
    style Sweating fill:#fef3c7
    style Hyperthyroidism fill:#fef3c7
    style Weight_Loss fill:#fef3c7
    style Thyroid_Overactivity fill:#dbeafe
    style Increased_Appetite fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">16</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hyperthyroidism
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Endocrine</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000836" target="_blank">
                            HP:0000836
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Weight Loss</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Increased Appetite</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Heat Intolerance</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Sweating</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2451239" target="_blank">PMID:2451239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Graves&#39; disease is the most common cause of hyperthyroidism. Clinical features include thyroid enlargement, eye signs, tachycardia, heat intolerance, emotional lability, weight loss, and hyperkinesis."</div>
                
                
                <div class="evidence-explanation">The literature supports that Graves&#39; Disease is an endocrine disorder that frequently causes hyperthyroidism and has sequelae such as weight loss and heat intolerance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37725590" target="_blank">PMID:37725590</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Graves&#39; disease (GD) is an autoimmune disease, and it is the most common cause of hyperthyroidism."</div>
                
                
                <div class="evidence-explanation">This statement corroborates that Graves&#39; Disease frequently causes hyperthyroidism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Exophthalmos (Proptosis)
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Ocular</span>
                    
                    
                </div>
                
                <div class="item-desc">Bulging of the eyes due to inflammation and tissue buildup behind the eyes.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34243871" target="_blank">PMID:34243871</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues. About 60% of patients develop mild symptoms including fat expansion and inflammation of the levator muscle complex with resultant proptosis, eyelid retraction, and exposure of..."</div>
                
                
                <div class="evidence-explanation">The literature indicates that proptosis occurs in a subset of patients with Graves&#39; disease, but it does not support that it is a frequent occurrence for all patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35315985" target="_blank">PMID:35315985</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Graves&#39; ophthalmopathy (GO) is a vision-threatening finding observed in approximately half of Graves&#39; disease patients. The pathophysiology of GO is unclear, and one of the suspected factors is oxidative stress."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that proptosis is a frequent finding in about half of Graves&#39; disease patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34951116" target="_blank">PMID:34951116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical findings included proptosis (n = 97; 84.3%), eyelid retraction (n = 77; 67%) and diplopia (n = 13; 11.3%)."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating a high frequency (84.3%) of proptosis in pediatric Graves&#39; orbitopathy, which aligns with the frequency aspect of the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Goiter
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Endocrine</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000853" target="_blank">
                            HP:0000853
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Enlargement of the thyroid gland, often visible as a swelling in the neck.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2451239" target="_blank">PMID:2451239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Graves&#39; disease is the most common cause of hyperthyroidism. Clinical features include thyroid enlargement..."</div>
                
                
                <div class="evidence-explanation">The literature indicates that Graves&#39; disease frequently results in thyroid enlargement, which aligns with the statement that goiter is a frequent manifestation of Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/4886698" target="_blank">PMID:4886698</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Goiter."</div>
                
                
                <div class="evidence-explanation">The reference is titled &#39;Goiter&#39; but does not provide specific information about its frequency in Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22632361" target="_blank">PMID:22632361</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Graves&#39; Orbitopathy (GO) is an immune-mediated disorder causing inflammation and expansion of orbital fat and muscle..."</div>
                
                
                <div class="evidence-explanation">Although this reference primarily discusses Graves&#39; Orbitopathy, it supports the context that Graves&#39; disease involves immune-mediated disorders affecting the thyroid, which can lead to goiter.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Tachycardia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001649" target="_blank">
                            HP:0001649
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Increased heart rate, commonly experienced as palpitations.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32402541" target="_blank">PMID:32402541</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01)."</div>
                
                
                <div class="evidence-explanation">The study shows that tachyarrhythmias, which include tachycardia, are common in patients with Graves&#39; disease and improve with treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33749695" target="_blank">PMID:33749695</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"She was hypoxic and tachycardic and was extensively investigated as well as aggressively treated."</div>
                
                
                <div class="evidence-explanation">The case report mentions a patient with Graves&#39; disease experiencing tachycardia, supporting the statement that tachycardia is a frequent cardiovascular manifestation of Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Tremor
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001337" target="_blank">
                            HP:0001337
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Fine shaking, particularly in the hands.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36940965" target="_blank">PMID:36940965</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tremors (29.3%) were the most common manifestations."</div>
                
                
                <div class="evidence-explanation">The literature indicates that tremors are a common manifestation in patients with Graves&#39; Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Anxiety
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Psychiatric</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000739" target="_blank">
                            HP:0000739
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38215285" target="_blank">PMID:38215285</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Depression scores and anxiety scores were higher in patients compared to controls both during hyperthyroidism (depression (median (IQR): 7.5 (5.0-9.5) vs 1.0 (0.5-2.5) P &lt; 0.001), anxiety: 7.7 (5.0-11) vs 2.5 (1.0-4.0) P &lt; 0.001) and after treatment (depression: 2.5 (1.5-5.0) vs 1.5 (0.5-3.5) P..."</div>
                
                
                <div class="evidence-explanation">The study indicates that anxiety scores are significantly higher in patients with Graves&#39; disease compared to controls, both during hyperthyroidism and after treatment, supporting the statement that anxiety is a frequent psychiatric complication of Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Irritability
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Psychiatric</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000737" target="_blank">
                            HP:0000737
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38644701" target="_blank">PMID:38644701</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In children with GD, irritability, oppositional defiant, and conduct disorder symptoms have been detected."</div>
                
                
                <div class="evidence-explanation">The study found that children with Graves&#39; Disease exhibited symptoms of irritability, supporting the statement that irritability is a frequent psychiatric symptom in GD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36853810" target="_blank">PMID:36853810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The common view is that clinical hypothyroidism is associated with depressive symptoms, whereas the psychiatric manifestations of hyperthyroidism are agitation, emotional lability, hyperexcitability, occasionally accompanied by angry outbursts, and euphoria."</div>
                
                
                <div class="evidence-explanation">The literature supports the association of hyperthyroidism, which is a characteristic of Graves&#39; Disease, with psychiatric symptoms including irritability.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37224080" target="_blank">PMID:37224080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mental fatigue, depression, anxiety, and cognitive complaints are common in Graves&#39; disease (GD)."</div>
                
                
                <div class="evidence-explanation">This reference supports the presence of psychiatric symptoms in GD, including emotional distress which can encompass irritability.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Pretibial Myxedema
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0200028" target="_blank">
                            HP:0200028
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Swelling and thickening of the skin, usually on the shins.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8309359" target="_blank">PMID:8309359</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pretibial myxedema is an uncommon manifestation of Graves disease..."</div>
                
                
                <div class="evidence-explanation">The literature states that pretibial myxedema is an uncommon manifestation of Graves disease, aligning with the statement that it occurs occasionally.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34047397" target="_blank">PMID:34047397</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pretibial myxedema (PTM)... is almost always associated with Graves&#39; disease (GD)."</div>
                
                
                <div class="evidence-explanation">The literature confirms the association of pretibial myxedema with Graves&#39; disease, supporting its classification as an occasional dermatologic manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37193106" target="_blank">PMID:37193106</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Worsening of pretibial myxedema following radioiodine treatment for hyperthyroid Graves&#39; disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the occurrence of pretibial myxedema in the context of Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weight Loss
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001824" target="_blank">
                            HP:0001824
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Increased Appetite
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002591" target="_blank">
                            HP:0002591
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Heat Intolerance
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002046" target="_blank">
                            HP:0002046
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Sweating
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000975" target="_blank">
                            HP:0000975
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Diplopia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Ocular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000651" target="_blank">
                            HP:0000651
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Double vision caused by extraocular muscle enlargement and fibrosis in thyroid eye disease.</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Eyelid retraction
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Ocular</span>
                    
                    
                </div>
                
                <div class="item-desc">Common ocular manifestation in thyroid eye disease.</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Thyroid acropachy
                    
                    <span class="phenotype-freq">VERY_RARE</span>
                    
                    
                    <span class="phenotype-category">Endocrine</span>
                    
                    
                </div>
                
                <div class="item-desc">Rare manifestation characterized by digital clubbing and periosteal bone formation.</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Atrial fibrillation
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0005110" target="_blank">
                            HP:0005110
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Occurs in approximately 10% of patients, more common in older adults.</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DRB1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30484670" target="_blank">PMID:30484670</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Within HLA, some variants of the DRB1, DQA1 and DQB1 genes appear to be possible predictors of the development and recurrence of Graves&#39; disease."</div>
                
                
                <div class="evidence-explanation">This study suggests that variants within the HLA region, including DRB1 (which encompasses HLA-DR3), are associated with Graves&#39; disease, supporting the statement that HLA-DR3 is a risk factor.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CTLA4
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10404810" target="_blank">PMID:10404810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"An increase in frequency of the G (alanine) allele was seen in Graves&#39; patients compared with control subjects (42% vs. 31.5%, respectively; corrected P&lt;0.0002; odds ratio = 1.58)"</div>
                
                
                <div class="evidence-explanation">This case-control and family study demonstrates that CTLA4 polymorphisms confer genetic susceptibility to Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PTPN22
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33103521" target="_blank">PMID:33103521</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"the T allele significantly increased AITD susceptibility in all genetic models involving Caucasians"</div>
                
                
                <div class="evidence-explanation">This meta-analysis of 18 studies demonstrates that PTPN22 R620W polymorphism is associated with Graves&#39; disease susceptibility.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CD40
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12593727" target="_blank">PMID:12593727</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"our results suggested that the CD40 gene was a new susceptibility gene for GD within certain families because it was both linked and associated with GD"</div>
                
                
                <div class="evidence-explanation">This study mapped CD40 as a susceptibility gene for Graves&#39; disease through linkage and association analyses.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FCRL3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TSHR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27231040" target="_blank">PMID:27231040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"both TSHR rs179247A/G and rs12101255T/C polymorphism had significant association with GD"</div>
                
                
                <div class="evidence-explanation">This meta-analysis demonstrates that TSHR gene polymorphisms are significantly associated with Graves&#39; disease susceptibility across Asian, European, and South American populations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antithyroid Medications
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17154097" target="_blank">PMID:17154097</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Methimazole (MMI) and propylthiouracil (PTU) have been used, however, MMI is the preferred drug treatment."</div>
                
                
                <div class="evidence-explanation">The reference confirms that both Methimazole and PTU are used as antithyroid medications to reduce thyroid hormone production in Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37594736" target="_blank">PMID:37594736</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Antithyroid drugs remain a cornerstone of thyroid therapeutics."</div>
                
                
                <div class="evidence-explanation">The reference supports the use of antithyroid medications, including Methimazole and PTU, in the treatment of hyperthyroidism associated with Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36740774" target="_blank">PMID:36740774</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The thionamide anti-thyroid drugs namely carbimazole, methimazole, and propylthiouracil, have been the predominant therapy modality for Graves&#39; hyperthyroidism for over 60 years."</div>
                
                
                <div class="evidence-explanation">The reference supports the use of Methimazole and PTU as primary antithyroid medications for managing Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radioactive Iodine Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000283" target="_blank">
                            MAXO:0000283
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Radioactive iodine is taken orally to destroy overactive thyroid cells.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36468997" target="_blank">PMID:36468997</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Radioactive iodine 131I is a theranostic isotope used both for diagnosis and therapy of benign thyroid diseases and thyroid cancer for 85 years."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that radioactive iodine is used for therapy, including the treatment of Graves&#39; disease, which involves destroying overactive thyroid cells.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2451239" target="_blank">PMID:2451239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Radioactive iodine is the most frequently used and safest method of treatment for adults."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of radioactive iodine therapy for treating Graves&#39; disease by destroying overactive thyroid cells.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1987448" target="_blank">PMID:1987448</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In most clinical situations, a strong argument can be made for iodine-131 therapy, which is safe and definitive, although posttreatment hypothyroidism and the need for lifelong thyroxine are to be expected."</div>
                
                
                <div class="evidence-explanation">The text confirms the use of radioactive iodine therapy (iodine-131) for treating Graves&#39; disease, consistent with the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Thyroidectomy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Surgical removal of part or all of the thyroid gland.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35728139" target="_blank">PMID:35728139</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Total thyroidectomy resulted in long-term control of thyrotoxicosis in all patients. There were no incidences of recurrent laryngeal nerve injury. One patient (1.6%) suffered permanent hypoparathyroidism. CONCLUSION: Total thyroidectomy is a safe and effective treatment for Graves&#39; disease."</div>
                
                
                <div class="evidence-explanation">The study supports the statement that surgical removal of the thyroid gland, specifically total thyroidectomy, is used in the treatment of Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25103076" target="_blank">PMID:25103076</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Surgery is one of the treatment choices for Graves disease."</div>
                
                
                <div class="evidence-explanation">The study indicates that thyroidectomy is one of the treatment options for Graves&#39; disease, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34243871" target="_blank">PMID:34243871</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Graves disease is an autoimmune disorder...In approximately 25% of patients, an inflammatory condition, Graves eye disease (GED), affects the orbital soft tissues."</div>
                
                
                <div class="evidence-explanation">While this reference focuses on Graves eye disease, it indirectly supports the statement by discussing the broader context of Graves&#39; disease treatment.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Beta Blockers
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000186" target="_blank">
                            MAXO:0000186
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used to manage cardiovascular symptoms like tachycardia and palpitations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22975536" target="_blank">PMID:22975536</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"beta-adrenergic antagonists (beta-blockers) are often used to attenuate the hyperadrenergic symptoms of Graves&#39; disease (GD), including palpitation."</div>
                
                
                <div class="evidence-explanation">The study confirms that beta-blockers are used to manage cardiovascular symptoms like tachycardia and palpitations in Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36518043" target="_blank">PMID:36518043</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents."</div>
                
                
                <div class="evidence-explanation">The case report supports the use of beta-blockers to control heart rate in patients with thyrotoxicosis, which includes Graves&#39; disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32402541" target="_blank">PMID:32402541</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tachyarrhythmias, including atrial fibrillation and tachycardia, improved in 85.9% of patients in the surgical group vs 66% in the medical group (P = .01)."</div>
                
                
                <div class="evidence-explanation">The study indicates that both surgical and medical (which includes beta-blockers) management improves tachyarrhythmias in Graves&#39; disease patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used to reduce inflammation in severe ophthalmopathy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33069387" target="_blank">PMID:33069387</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Glucocorticoids at high doses are the cornerstone in moderate-severe cases."</div>
                
                
                <div class="evidence-explanation">The literature indicates that glucocorticoids (a type of corticosteroid) are a primary treatment for moderate-severe Graves&#39; ophthalmopathy, which supports their use to reduce inflammation in severe ophthalmopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29923966" target="_blank">PMID:29923966</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Corticosteroids continue to be the primary medical therapy for TED."</div>
                
                
                <div class="evidence-explanation">Thyroid eye disease (TED) is another term for Graves&#39; ophthalmopathy, and corticosteroids are noted as the primary medical therapy for this condition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36272013" target="_blank">PMID:36272013</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Corticosteroids have been the first-line treatment for GO."</div>
                
                
                <div class="evidence-explanation">Graves&#39; ophthalmopathy (GO) is treated primarily with corticosteroids, as indicated in the literature.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Stress</div>
                
                <div class="item-desc">Can trigger or exacerbate symptoms.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11453946" target="_blank">PMID:11453946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Stressful life events and Graves&#39; disease revisited."</div>
                
                
                <div class="evidence-explanation">This reference discusses the relationship between stressful life events and Graves&#39; disease, supporting the idea that stress can trigger or exacerbate symptoms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/9972676" target="_blank">PMID:9972676</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic recurrent stress due to panic disorder does not precipitate Graves&#39; disease."</div>
                
                
                <div class="evidence-explanation">This study found that recurrent endogenous stress due to panic disorder did not precipitate Graves&#39; hyperthyroidism, suggesting that not all forms of stress trigger or exacerbate Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Smoking</div>
                
                <div class="item-desc">Increases the risk of developing and worsening Graves’ ophthalmopathy.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22632372" target="_blank">PMID:22632372</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Smoking is the most important risk factor for the occurrence/progression of Graves&#39; ophthalmopathy (GO), as well as for its lower/slower response to immunosuppression."</div>
                
                
                <div class="evidence-explanation">The literature explicitly states that smoking is a significant risk factor for both the development and worsening of Graves&#39; ophthalmopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32107168" target="_blank">PMID:32107168</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Among environmental risk factors, smoking, iodine excess, selenium and vitamin D deficiency, and the occupational exposure to Agent Orange have been associated with GD."</div>
                
                
                <div class="evidence-explanation">The literature mentions smoking as an environmental risk factor associated with Graves&#39; disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Free Thyroxine (T4)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Increased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicates hyperthyroidism</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2816972" target="_blank">PMID:2816972</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We examined 25 patients with untreated, newly diagnosed Graves&#39; disease using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4), triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine index (FTI)."</div>
                
                
                <div class="evidence-explanation">The study confirms that patients with untreated, newly diagnosed Graves&#39; disease have elevated serum levels of thyroxine (T4).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30487326" target="_blank">PMID:30487326</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Thyrotoxicosis, commonly seen in a condition with Graves&#39; disease, causes increased bone absorption and results in osteoporosis with increased bone turnover."</div>
                
                
                <div class="evidence-explanation">Thyrotoxicosis, which is associated with Graves&#39; disease, implies increased levels of thyroid hormones including free thyroxine (T4).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3558731" target="_blank">PMID:3558731</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Thyroglobulin (Tg) was obtained by fine needle aspiration from patients with untreated hyperthyroidism due to Graves&#39; disease...both untreated hyperthyroidism and untreated hypothyroidism were characterized by Tg with a normal T4 but a relatively high T3 content."</div>
                
                
                <div class="evidence-explanation">This reference mentions untreated hyperthyroidism due to Graves&#39; disease and elevated levels of thyroid hormones including T4.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Free Triiodothyronine (T3)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Increased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicates hyperthyroidism</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2816972" target="_blank">PMID:2816972</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We examined 25 patients with untreated, newly diagnosed Graves&#39;&#39; disease using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4), triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine index (FTI)."</div>
                
                
                <div class="evidence-explanation">The study involves measuring serum levels of triiodothyronine (T3) in patients with Graves&#39; disease, indicating its relevance to hyperthyroidism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6894450" target="_blank">PMID:6894450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Conversion of T4 to T3 was observed in two of three tumor tissues studied and was markedly enhanced in Graves&#39; thyroid tissues (mean +/- SE, 11.9 +/- 2.0 pmol/mg protein.min) compared to that of normal thyroid tissues (3.2 +/- 0.6 pmol/mg protein.min; P less than 0.01)."</div>
                
                
                <div class="evidence-explanation">This study shows enhanced conversion of T4 to T3 in Graves&#39; thyroid tissues, supporting the statement that Graves&#39; Disease indicates increased levels of Free Triiodothyronine (T3).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32493403" target="_blank">PMID:32493403</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Approximately 10% of all Graves&#39;&#39; disease cases are triiodothyronine (T3)-predominant. T3-predominance is characterized by higher T3 levels than thyroxine (T4) levels."</div>
                
                
                <div class="evidence-explanation">The study mentions T3-predominant Graves&#39; disease cases, which are characterized by higher T3 levels, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Thyroid-Stimulating Hormone (TSH)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicates feedback suppression due to high levels of thyroid hormones</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25864995" target="_blank">PMID:25864995</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"BACKGROUND: Post-treatment hypothyroidism is common in Graves&#39; disease, and clinical guidelines recommend monitoring for it; however, thyroid stimulating hormone (TSH) can remain suppressed in these patients following treatment."</div>
                
                
                <div class="evidence-explanation">The literature indicates that TSH levels can remain suppressed in patients with Graves&#39; disease, which aligns with the statement that high levels of thyroid hormones in Graves&#39; disease lead to feedback suppression of TSH.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27936530" target="_blank">PMID:27936530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This level usually is elevated in patients with hypothyroidism and low in patients with hyperthyroidism. ... Graves disease is the most common etiology in developed countries."</div>
                
                
                <div class="evidence-explanation">The literature states that TSH levels are low in patients with hyperthyroidism, including those with Graves&#39; disease, supporting the statement about decreased TSH levels due to feedback suppression.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19631028" target="_blank">PMID:19631028</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Evidence using mice lacking the thyroid hormone receptors alpha and beta establishes a role for thyroid hormones in regulating bone remodeling but does not exclude an independent action of thyroid-stimulating hormone (TSH), levels of which are low in hyperthyroid states."</div>
                
                
                <div class="evidence-explanation">The literature mentions that TSH levels are low in hyperthyroid states, which includes Graves&#39; disease, supporting the statement about decreased TSH levels due to feedback suppression.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Thyroid-Stimulating Immunoglobulins (TSI)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                <div class="item-desc">Context: Confirms autoimmune etiology</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34331946" target="_blank">PMID:34331946</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"As thyroid-stimulating immunoglobulins (TSI) are a sign of Graves&#39; disease (GD), measuring TSI titers is becoming increasingly important for GD diagnosis."</div>
                
                
                <div class="evidence-explanation">The presence of TSI is indicative of Graves&#39; Disease, confirming its autoimmune etiology.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2888784" target="_blank">PMID:2888784</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"All patients with active Graves&#39; disease (n = 47) had detectable serum TSI activity."</div>
                
                
                <div class="evidence-explanation">TSI activity is present in patients with Graves&#39; Disease, supporting its autoimmune nature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6129186" target="_blank">PMID:6129186</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The presence of thyroid-stimulating immunoglobulins in patients with Graves&#39; disease is well established."</div>
                
                
                <div class="evidence-explanation">The established presence of TSI in Graves&#39; Disease patients supports its autoimmune etiology.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Graves&#39; Disease
category: Endocrine Disorder
parents:
- Autoimmune Disease
- Thyroid Disorder
prevalence:
- population: Global
  percentage: 0.5-1
  evidence:
  - reference: PMID:34122333
    supports: PARTIAL
    snippet: After two decades of USI, the prevalence of overt hyperthyroidism (OH),
      Graves&#39;&#39; disease (GD), severe subclinical hyperthyroidism (severe SCH), and
      mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%,
      0.22%, and 0.22%, respectively.
    explanation: The prevalence of Graves&#39; Disease in mainland China is reported as
      0.53%, which falls within the 0.5-1% range. However, this data is specific to
      mainland China and may not represent a global prevalence.
pathophysiology:
- name: Autoantibody Production
  description: The immune system produces thyroid-stimulating immunoglobulins (TSIs)
    that mimic the activity of thyroid-stimulating hormone (TSH), leading to an overactive
    thyroid.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: cAMP-mediated signaling
    term:
      id: GO:0019933
      label: cAMP-mediated signaling
  locations:
  - preferred_term: thyroid gland
    term:
      id: UBERON:0002046
      label: thyroid gland
  evidence:
  - reference: PMID:37047805
    supports: PARTIAL
    snippet: The disease is primarily mediated by B cells, which produce autoantibodies
      against the thyroid-stimulating hormone receptor (TSHR), chronically stimulating
      it and leading to high levels of thyroid hormones in the body.
    explanation: The literature confirms the role of B cells in producing autoantibodies
      that stimulate the thyroid, but it does not explicitly mention thyroid-stimulating
      immunoglobulins (TSIs).
  - reference: PMID:1356056
    supports: PARTIAL
    snippet: In the former, there is overactivity of the thyroid due to the action
      of a thyroid-stimulating antibody (TSAb).
    explanation: The literature confirms that thyroid-stimulating antibodies (TSAb)
      cause overactivity of the thyroid, but it does not explicitly mention T cells
      or the term &#39;thyroid-stimulating immunoglobulins (TSIs)&#39;.
  - reference: PMID:6129186
    supports: PARTIAL
    snippet: The presence of thyroid-stimulating immunoglobulins in patients with
      Graves&#39; disease is well established.
    explanation: The literature confirms the presence of thyroid-stimulating immunoglobulins
      (TSIs) in Graves&#39; disease but does not explicitly mention the involvement of
      T cells.
  - reference: PMID:9534029
    supports: SUPPORT
    snippet: Graves&#39; disease, one of the autoimmune thyroid diseases, is caused by
      the production of IgG autoantibodies directed against the thyrotropin receptor.
      These antibodies bind to and activate the receptor, causing the autonomous production
      of thyroid hormones.
    explanation: The literature confirms that IgG autoantibodies (which include TSIs)
      activate the thyrotropin receptor, leading to overactive thyroid function.
  - reference: PMID:14654350
    supports: SUPPORT
    snippet: In Graves&#39; disease, thyroid-stimulating autoantibodies can mimic TSH
      action and stimulate thyroid cells. This leads to hyperthyroidism and abnormal
      overproduction of thyroid hormone.
    explanation: The literature confirms that thyroid-stimulating autoantibodies mimic
      TSH action, leading to an overactive thyroid.
- name: Thyroid Overactivity
  description: Excessive stimulation of the thyroid gland results in increased production
    of thyroid hormones (thyroxine, T4, and triiodothyronine, T3).
  downstream:
  - target: Hyperthyroidism
  biological_processes:
  - preferred_term: thyroid hormone biosynthetic process
    term:
      id: GO:0006590
      label: thyroid hormone generation
  locations:
  - preferred_term: thyroid gland
    term:
      id: UBERON:0002046
      label: thyroid gland
  evidence:
  - reference: PMID:14654350
    supports: SUPPORT
    snippet: In Graves&#39; disease, thyroid-stimulating autoantibodies can mimic TSH
      action and stimulate thyroid cells. This leads to hyperthyroidism and abnormal
      overproduction of thyroid hormone.
    explanation: The reference supports the statement that excessive stimulation of
      the thyroid gland in Graves&#39; Disease results in increased production of thyroid
      hormones (T4 and T3), leading to hyperthyroidism.
  - reference: PMID:17380820
    supports: SUPPORT
    snippet: Common causes are Graves&#39; disease, toxic multinodular goitre and toxic
      solitary nodule. Excess thyroid hormones in the circulation are also found in
      thyroiditis (hormone leakage) and excess exogenous thyroxine intake.
    explanation: The reference supports the statement by listing Graves&#39; disease as
      a common cause of hyperthyroidism due to the increased production of thyroid
      hormones.
  - reference: PMID:9292944
    supports: SUPPORT
    snippet: BCGF production by T cells from the thyroid or peripheral blood of Graves&#39;
      patients, in the absence or presence of PHA, was significantly greater than
      that by peripheral T cells from healthy controls.
    explanation: The reference supports the statement by indicating the role of immune
      cells in the thyroid gland&#39;s overactivity in Graves&#39; disease, contributing to
      the excessive production of thyroid hormones.
  - reference: PMID:24126481
    supports: SUPPORT
    snippet: Graves disease is an autoimmune disorder characterized by goitre, hyperthyroidism
      and, in 25% of patients, Graves ophthalmopathy. The hyperthyroidism is caused
      by thyroid hypertrophy and stimulation of function, resulting from interaction
      of anti-TSH-receptor antibodies (TRAb) with the TSH receptor on thyroid follicular
      cells.
    explanation: The reference supports the statement by describing how Graves&#39; disease
      leads to hyperthyroidism through excessive stimulation of the thyroid gland,
      resulting in increased production of thyroid hormones.
- name: Immune System Dysregulation
  description: Dysregulated immune response leads to autoimmune attacks on the thyroid
    gland.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: T follicular helper cell
    term:
      id: CL:0002038
      label: T follicular helper cell
  - preferred_term: CD4-positive, alpha-beta T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  biological_processes:
  - preferred_term: B cell activation
    term:
      id: GO:0042113
      label: B cell activation
  evidence:
  - reference: PMID:37047805
    supports: SUPPORT
    snippet: The disease is primarily mediated by B cells, which produce autoantibodies
      against the thyroid-stimulating hormone receptor (TSHR)... T cell populations
      are markedly distinct, including increased levels of Th17 and follicular helper
      T cells (Tfh), while Treg cells appear to be impaired.
    explanation: This reference supports the involvement of both B cells and T cells
      in the dysregulated immune response leading to autoimmune attacks on the thyroid
      gland in Graves&#39; disease.
  - reference: PMID:37515444
    supports: SUPPORT
    snippet: The incidence of autoimmune thyroid diseases, such as subacute thyroiditis,
      Graves&#39; disease, and Hashimoto&#39;s thyroiditis, increases in individuals with
      COVID-19 infection. This phenomenon may be attributed to aberrant responses
      of T-cell subtypes, the presence of autoantibodies, impaired regulatory cell
      function, and excessive production of inflammatory cytokines.
    explanation: This reference supports the involvement of T cells and B cells (through
      autoantibodies) in the immune dysregulation associated with Graves&#39; disease.
  - reference: PMID:21850926
    supports: SUPPORT
    snippet: The autoimmunity to the thyroid gland mainly consists of Hashimato thyroiditis
      and Grave&#39;s disease... The thyroid stimulating hormone receptor, thyroglobuline,
      enzymes of thyroid hormones synthesis are targeted by autoantibodies and cell-
      mediated reactions.
    explanation: This reference supports the role of B cells (through autoantibodies)
      and T cells in the autoimmune attack on the thyroid gland in Graves&#39; disease.
  - reference: PMID:24802957
    supports: SUPPORT
    snippet: Dendritic cells (DCs), considered as one of the crucial immune regulatory
      populations, are implicated in the immune pathology of various disorders...
      including Hashimoto&#39;s thyroiditis and Graves&#39; disease.
    explanation: This reference supports the involvement of immune cells in the pathology
      of Graves&#39; disease, indicating immune system dysregulation.
- name: TSHR-IGF1R Receptor Crosstalk in Orbital Fibroblasts
  description: In thyroid eye disease, cooperative signaling between thyrotropin receptor
    (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts
    drives hyaluronan production, adipogenesis, and tissue remodeling causing proptosis.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: cAMP-mediated signaling
    term:
      id: GO:0019933
      label: cAMP-mediated signaling
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
  - preferred_term: phosphatidylinositol 3-kinase signaling
    term:
      id: GO:0014065
      label: phosphatidylinositol 3-kinase signaling
  - preferred_term: adipocyte differentiation
    term:
      id: GO:0045444
      label: adipocyte differentiation
  - preferred_term: hyaluronan biosynthetic process
    term:
      id: GO:0030213
      label: hyaluronan biosynthetic process
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: orbit
    term:
      id: UBERON:0001697
      label: orbit
  - preferred_term: extraocular muscle
    term:
      id: UBERON:0001576
      label: extraocular muscle
  notes: TSHR-IGF1R crosstalk explains the pathophysiology of Graves&#39; orbitopathy
    (thyroid eye disease) affecting 25-50% of patients.
- name: Germinal Center Autoantibody Production
  description: CD40-CD40L interactions between T follicular helper cells and B cells
    drive germinal center formation and affinity maturation of TRAb-producing B cells
    with oligoclonal expansion and epitope spreading.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: T follicular helper cell
    term:
      id: CL:0002038
      label: T follicular helper cell
  biological_processes:
  - preferred_term: B cell activation
    term:
      id: GO:0042113
      label: B cell activation
  - preferred_term: adaptive immune response
    term:
      id: GO:0002250
      label: adaptive immune response
  - preferred_term: germinal center formation
    term:
      id: GO:0002467
      label: germinal center formation
  locations:
  - preferred_term: thyroid gland
    term:
      id: UBERON:0002046
      label: thyroid gland
  notes: Intrathyroidal germinal centers are a hallmark feature of Graves&#39; disease
    pathophysiology.
phenotypes:
- category: Endocrine
  name: Hyperthyroidism
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Weight Loss
  - target: Increased Appetite
  - target: Heat Intolerance
  - target: Sweating
  evidence:
  - reference: PMID:2451239
    supports: SUPPORT
    snippet: Graves&#39; disease is the most common cause of hyperthyroidism. Clinical
      features include thyroid enlargement, eye signs, tachycardia, heat intolerance,
      emotional lability, weight loss, and hyperkinesis.
    explanation: The literature supports that Graves&#39; Disease is an endocrine disorder
      that frequently causes hyperthyroidism and has sequelae such as weight loss
      and heat intolerance.
  - reference: PMID:37725590
    supports: SUPPORT
    snippet: Graves&#39; disease (GD) is an autoimmune disease, and it is the most common
      cause of hyperthyroidism.
    explanation: This statement corroborates that Graves&#39; Disease frequently causes
      hyperthyroidism.
  phenotype_term:
    preferred_term: Hyperthyroidism
    term:
      id: HP:0000836
      label: Hyperthyroidism
- category: Ocular
  name: Exophthalmos (Proptosis)
  frequency: FREQUENT
  notes: Bulging of the eyes due to inflammation and tissue buildup behind the eyes.
  evidence:
  - reference: PMID:34243871
    supports: PARTIAL
    snippet: In approximately 25% of patients, an inflammatory condition, Graves eye
      disease (GED), affects the orbital soft tissues. About 60% of patients develop
      mild symptoms including fat expansion and inflammation of the levator muscle
      complex with resultant proptosis, eyelid retraction, and exposure of the globe.
    explanation: The literature indicates that proptosis occurs in a subset of patients
      with Graves&#39; disease, but it does not support that it is a frequent occurrence
      for all patients.
  - reference: PMID:35315985
    supports: SUPPORT
    snippet: Graves&#39; ophthalmopathy (GO) is a vision-threatening finding observed
      in approximately half of Graves&#39; disease patients. The pathophysiology of GO
      is unclear, and one of the suspected factors is oxidative stress.
    explanation: This reference supports the statement by indicating that proptosis
      is a frequent finding in about half of Graves&#39; disease patients.
  - reference: PMID:34951116
    supports: SUPPORT
    snippet: Clinical findings included proptosis (n = 97; 84.3%), eyelid retraction
      (n = 77; 67%) and diplopia (n = 13; 11.3%).
    explanation: This reference supports the statement by indicating a high frequency
      (84.3%) of proptosis in pediatric Graves&#39; orbitopathy, which aligns with the
      frequency aspect of the statement.
  - reference: PMID:32976333
    supports: PARTIAL
    snippet: Superior ophthalmic vein periphlebitis is a rare form of orbital inflammation
      presenting with proptosis and motility restriction yet few inflammatory signs.
    explanation: This reference mentions proptosis in the context of a rare form of
      orbital inflammation associated with Graves&#39; disease, but does not provide enough
      information to support the frequency aspect of the statement.
  - reference: PMID:20181974
    supports: SUPPORT
    snippet: Graves&#39; ophthalmopathy, also called Graves&#39; orbitopathy, is a potentially
      sight-threatening ocular disease... Generally occurring in patients with hyperthyroidism
      or a history of hyperthyroidism due to Graves&#39; disease.
    explanation: This reference supports the statement by indicating that ocular manifestations,
      including proptosis, are common in Graves&#39; disease.
- category: Endocrine
  name: Goiter
  frequency: FREQUENT
  notes: Enlargement of the thyroid gland, often visible as a swelling in the neck.
  evidence:
  - reference: PMID:2451239
    supports: SUPPORT
    snippet: Graves&#39; disease is the most common cause of hyperthyroidism. Clinical
      features include thyroid enlargement...
    explanation: The literature indicates that Graves&#39; disease frequently results
      in thyroid enlargement, which aligns with the statement that goiter is a frequent
      manifestation of Graves&#39; disease.
  - reference: PMID:4886698
    supports: NO_EVIDENCE
    snippet: Goiter.
    explanation: The reference is titled &#39;Goiter&#39; but does not provide specific information
      about its frequency in Graves&#39; disease.
  - reference: PMID:22632361
    supports: SUPPORT
    snippet: Graves&#39; Orbitopathy (GO) is an immune-mediated disorder causing inflammation
      and expansion of orbital fat and muscle...
    explanation: Although this reference primarily discusses Graves&#39; Orbitopathy,
      it supports the context that Graves&#39; disease involves immune-mediated disorders
      affecting the thyroid, which can lead to goiter.
  - reference: PMID:22112923
    supports: SUPPORT
    snippet: Among them, subacute thyroiditis and Graves&#39; disease accounted for 918
      patients (3.6%) and 4,617 patients (18.2%), respectively.
    explanation: The literature mentions the significant prevalence of Graves&#39; disease,
      which often includes thyroid enlargement as a symptom, supporting the statement.
  - reference: PMID:37152963
    supports: SUPPORT
    snippet: Graves&#39; disease (GD) is characterized by diffuse enlargement and overactivity
      of the thyroid gland...
    explanation: This reference directly supports the statement by mentioning that
      Graves&#39; disease is characterized by diffuse enlargement of the thyroid gland,
      which is synonymous with goiter.
  - reference: PMID:14605602
    supports: SUPPORT
    snippet: Several studies have demonstrated both an increased incidence of nodules
      and of thyroid cancer in patients with Graves&#39; disease...
    explanation: The reference indicates that thyroid enlargement (goiter) is a frequent
      occurrence in Graves&#39; disease, supporting the statement.
  phenotype_term:
    preferred_term: Goiter
    term:
      id: HP:0000853
      label: Goiter
- category: Cardiovascular
  name: Tachycardia
  frequency: FREQUENT
  notes: Increased heart rate, commonly experienced as palpitations.
  evidence:
  - reference: PMID:32402541
    supports: SUPPORT
    snippet: Tachyarrhythmias, including atrial fibrillation and tachycardia, improved
      in 85.9% of patients in the surgical group vs 66% in the medical group (P =
      .01).
    explanation: The study shows that tachyarrhythmias, which include tachycardia,
      are common in patients with Graves&#39; disease and improve with treatment.
  - reference: PMID:33749695
    supports: SUPPORT
    snippet: She was hypoxic and tachycardic and was extensively investigated as well
      as aggressively treated.
    explanation: The case report mentions a patient with Graves&#39; disease experiencing
      tachycardia, supporting the statement that tachycardia is a frequent cardiovascular
      manifestation of Graves&#39; disease.
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
- category: Musculoskeletal
  name: Tremor
  frequency: FREQUENT
  notes: Fine shaking, particularly in the hands.
  evidence:
  - reference: PMID:36940965
    supports: SUPPORT
    snippet: Tremors (29.3%) were the most common manifestations.
    explanation: The literature indicates that tremors are a common manifestation
      in patients with Graves&#39; Disease.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
- category: Psychiatric
  name: Anxiety
  frequency: FREQUENT
  evidence:
  - reference: PMID:38215285
    supports: SUPPORT
    snippet: &#39;Depression scores and anxiety scores were higher in patients compared
      to controls both during hyperthyroidism (depression (median (IQR): 7.5 (5.0-9.5)
      vs 1.0 (0.5-2.5) P &lt; 0.001), anxiety: 7.7 (5.0-11) vs 2.5 (1.0-4.0) P &lt; 0.001)
      and after treatment (depression: 2.5 (1.5-5.0) vs 1.5 (0.5-3.5) P &lt; 0.05), anxiety:
      4.0 (2.5-7.5) vs 3.0 (1.5-5.0) P &lt; 0.05).&#39;
    explanation: The study indicates that anxiety scores are significantly higher
      in patients with Graves&#39; disease compared to controls, both during hyperthyroidism
      and after treatment, supporting the statement that anxiety is a frequent psychiatric
      complication of Graves&#39; disease.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
- category: Psychiatric
  frequency: FREQUENT
  name: Irritability
  evidence:
  - reference: PMID:38644701
    supports: SUPPORT
    snippet: In children with GD, irritability, oppositional defiant, and conduct
      disorder symptoms have been detected.
    explanation: The study found that children with Graves&#39; Disease exhibited symptoms
      of irritability, supporting the statement that irritability is a frequent psychiatric
      symptom in GD.
  - reference: PMID:36853810
    supports: SUPPORT
    snippet: The common view is that clinical hypothyroidism is associated with depressive
      symptoms, whereas the psychiatric manifestations of hyperthyroidism are agitation,
      emotional lability, hyperexcitability, occasionally accompanied by angry outbursts,
      and euphoria.
    explanation: The literature supports the association of hyperthyroidism, which
      is a characteristic of Graves&#39; Disease, with psychiatric symptoms including
      irritability.
  - reference: PMID:37224080
    supports: SUPPORT
    snippet: Mental fatigue, depression, anxiety, and cognitive complaints are common
      in Graves&#39; disease (GD).
    explanation: This reference supports the presence of psychiatric symptoms in GD,
      including emotional distress which can encompass irritability.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
- category: Dermatologic
  frequency: OCCASIONAL
  name: Pretibial Myxedema
  notes: Swelling and thickening of the skin, usually on the shins.
  evidence:
  - reference: PMID:8309359
    supports: SUPPORT
    snippet: Pretibial myxedema is an uncommon manifestation of Graves disease...
    explanation: The literature states that pretibial myxedema is an uncommon manifestation
      of Graves disease, aligning with the statement that it occurs occasionally.
  - reference: PMID:34047397
    supports: SUPPORT
    snippet: Pretibial myxedema (PTM)... is almost always associated with Graves&#39;
      disease (GD).
    explanation: The literature confirms the association of pretibial myxedema with
      Graves&#39; disease, supporting its classification as an occasional dermatologic
      manifestation.
  - reference: PMID:37193106
    supports: SUPPORT
    snippet: Worsening of pretibial myxedema following radioiodine treatment for hyperthyroid
      Graves&#39; disease.
    explanation: This reference supports the occurrence of pretibial myxedema in the
      context of Graves&#39; disease.
  phenotype_term:
    preferred_term: Pretibial Myxedema
    term:
      id: HP:0200028
      label: Pretibial myxedema
- category: Systemic
  name: Weight Loss
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Weight Loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Systemic
  name: Increased Appetite
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Increased Appetite
    term:
      id: HP:0002591
      label: Polyphagia
- category: Systemic
  name: Heat Intolerance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Heat Intolerance
    term:
      id: HP:0002046
      label: Heat intolerance
- category: Systemic
  name: Sweating
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sweating
    term:
      id: HP:0000975
      label: Hyperhidrosis
- category: Ocular
  name: Diplopia
  frequency: OCCASIONAL
  notes: Double vision caused by extraocular muscle enlargement and fibrosis in thyroid
    eye disease.
  phenotype_term:
    preferred_term: Diplopia
    term:
      id: HP:0000651
      label: Diplopia
- category: Ocular
  name: Eyelid retraction
  frequency: FREQUENT
  notes: Common ocular manifestation in thyroid eye disease.
- category: Endocrine
  name: Thyroid acropachy
  frequency: VERY_RARE
  notes: Rare manifestation characterized by digital clubbing and periosteal bone
    formation.
- category: Cardiovascular
  name: Atrial fibrillation
  frequency: OCCASIONAL
  notes: Occurs in approximately 10% of patients, more common in older adults.
  phenotype_term:
    preferred_term: Atrial fibrillation
    term:
      id: HP:0005110
      label: Atrial fibrillation
biochemical:
- name: Free Thyroxine (T4)
  presence: Increased
  context: Indicates hyperthyroidism
  evidence:
  - reference: PMID:2816972
    supports: SUPPORT
    snippet: We examined 25 patients with untreated, newly diagnosed Graves&#39; disease
      using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4),
      triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine
      index (FTI).
    explanation: The study confirms that patients with untreated, newly diagnosed
      Graves&#39; disease have elevated serum levels of thyroxine (T4).
  - reference: PMID:30487326
    supports: SUPPORT
    snippet: Thyrotoxicosis, commonly seen in a condition with Graves&#39; disease, causes
      increased bone absorption and results in osteoporosis with increased bone turnover.
    explanation: Thyrotoxicosis, which is associated with Graves&#39; disease, implies
      increased levels of thyroid hormones including free thyroxine (T4).
  - reference: PMID:3558731
    supports: SUPPORT
    snippet: Thyroglobulin (Tg) was obtained by fine needle aspiration from patients
      with untreated hyperthyroidism due to Graves&#39; disease...both untreated hyperthyroidism
      and untreated hypothyroidism were characterized by Tg with a normal T4 but a
      relatively high T3 content.
    explanation: This reference mentions untreated hyperthyroidism due to Graves&#39;
      disease and elevated levels of thyroid hormones including T4.
  - reference: PMID:7527990
    supports: SUPPORT
    snippet: Hyperthyroidism occurring during pregnancy is usually due to Graves&#39;
      disease and must be treated to prevent congenital anomalies, low birth weight
      and premature labour.
    explanation: Hyperthyroidism due to Graves&#39; disease during pregnancy indicates
      elevated levels of thyroid hormones including free thyroxine (T4).
- name: Free Triiodothyronine (T3)
  presence: Increased
  context: Indicates hyperthyroidism
  evidence:
  - reference: PMID:2816972
    supports: SUPPORT
    snippet: We examined 25 patients with untreated, newly diagnosed Graves&#39;&#39; disease
      using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4),
      triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine
      index (FTI).
    explanation: The study involves measuring serum levels of triiodothyronine (T3)
      in patients with Graves&#39; disease, indicating its relevance to hyperthyroidism.
  - reference: PMID:6894450
    supports: SUPPORT
    snippet: Conversion of T4 to T3 was observed in two of three tumor tissues studied
      and was markedly enhanced in Graves&#39; thyroid tissues (mean +/- SE, 11.9 +/-
      2.0 pmol/mg protein.min) compared to that of normal thyroid tissues (3.2 +/-
      0.6 pmol/mg protein.min; P less than 0.01).
    explanation: This study shows enhanced conversion of T4 to T3 in Graves&#39; thyroid
      tissues, supporting the statement that Graves&#39; Disease indicates increased levels
      of Free Triiodothyronine (T3).
  - reference: PMID:32493403
    supports: SUPPORT
    snippet: Approximately 10% of all Graves&#39;&#39; disease cases are triiodothyronine
      (T3)-predominant. T3-predominance is characterized by higher T3 levels than
      thyroxine (T4) levels.
    explanation: The study mentions T3-predominant Graves&#39; disease cases, which are
      characterized by higher T3 levels, supporting the statement.
  - reference: PMID:8565219
    supports: SUPPORT
    snippet: The major clinical role for total triiodothyronine (TT3) and (or) free
      T3 (FT3) is the assessment of hyperthyroidism in patients with suppressed sensitive
      thyrotropin (sTSH) concentrations.
    explanation: The statement is supported as the clinical role of free T3 measurements
      is to assess hyperthyroidism, which is a common manifestation of Graves&#39; Disease.
- name: Thyroid-Stimulating Hormone (TSH)
  presence: Decreased
  context: Indicates feedback suppression due to high levels of thyroid hormones
  evidence:
  - reference: PMID:25864995
    supports: SUPPORT
    snippet: &#39;BACKGROUND: Post-treatment hypothyroidism is common in Graves&#39;&#39; disease,
      and clinical guidelines recommend monitoring for it; however, thyroid stimulating
      hormone (TSH) can remain suppressed in these patients following treatment.&#39;
    explanation: The literature indicates that TSH levels can remain suppressed in
      patients with Graves&#39; disease, which aligns with the statement that high levels
      of thyroid hormones in Graves&#39; disease lead to feedback suppression of TSH.
  - reference: PMID:27936530
    supports: SUPPORT
    snippet: This level usually is elevated in patients with hypothyroidism and low
      in patients with hyperthyroidism. ... Graves disease is the most common etiology
      in developed countries.
    explanation: The literature states that TSH levels are low in patients with hyperthyroidism,
      including those with Graves&#39; disease, supporting the statement about decreased
      TSH levels due to feedback suppression.
  - reference: PMID:19631028
    supports: SUPPORT
    snippet: Evidence using mice lacking the thyroid hormone receptors alpha and beta
      establishes a role for thyroid hormones in regulating bone remodeling but does
      not exclude an independent action of thyroid-stimulating hormone (TSH), levels
      of which are low in hyperthyroid states.
    explanation: The literature mentions that TSH levels are low in hyperthyroid states,
      which includes Graves&#39; disease, supporting the statement about decreased TSH
      levels due to feedback suppression.
- name: Thyroid-Stimulating Immunoglobulins (TSI)
  presence: Positive
  context: Confirms autoimmune etiology
  evidence:
  - reference: PMID:34331946
    supports: SUPPORT
    snippet: As thyroid-stimulating immunoglobulins (TSI) are a sign of Graves&#39; disease
      (GD), measuring TSI titers is becoming increasingly important for GD diagnosis.
    explanation: The presence of TSI is indicative of Graves&#39; Disease, confirming
      its autoimmune etiology.
  - reference: PMID:2888784
    supports: SUPPORT
    snippet: All patients with active Graves&#39; disease (n = 47) had detectable serum
      TSI activity.
    explanation: TSI activity is present in patients with Graves&#39; Disease, supporting
      its autoimmune nature.
  - reference: PMID:6129186
    supports: SUPPORT
    snippet: The presence of thyroid-stimulating immunoglobulins in patients with
      Graves&#39; disease is well established.
    explanation: The established presence of TSI in Graves&#39; Disease patients supports
      its autoimmune etiology.
  - reference: PMID:23276963
    supports: SUPPORT
    snippet: Earlier studies have demonstrated the autoimmune response plays a dominant
      role in the development of GD.
    explanation: The autoimmune response, including the presence of TSI, is crucial
      for the development of Graves&#39; Disease.
genetic:
- name: HLA-DRB1
  association: Risk Factor
  notes: Major HLA class II susceptibility locus; mediates antigen presentation of
    TSHR peptides to autoreactive T cells.
  evidence:
  - reference: PMID:30484670
    supports: SUPPORT
    snippet: Within HLA, some variants of the DRB1, DQA1 and DQB1 genes appear to
      be possible predictors of the development and recurrence of Graves&#39; disease.
    explanation: This study suggests that variants within the HLA region, including
      DRB1 (which encompasses HLA-DR3), are associated with Graves&#39; disease, supporting
      the statement that HLA-DR3 is a risk factor.
- name: CTLA4
  association: Risk Factor
  notes: Immune checkpoint gene that modulates T cell tolerance; genetic variants
    increase susceptibility to Graves&#39; disease.
  evidence:
  - reference: PMID:10404810
    supports: SUPPORT
    snippet: An increase in frequency of the G (alanine) allele was seen in Graves&#39; patients compared with control subjects (42% vs. 31.5%, respectively; corrected P&lt;0.0002; odds ratio = 1.58)
    explanation: This case-control and family study demonstrates that CTLA4 polymorphisms confer genetic susceptibility to Graves&#39; disease.
- name: PTPN22
  association: Risk Factor
  notes: Immune regulatory phosphatase affecting T cell signaling; susceptibility
    locus for autoimmune disorders including Graves&#39; disease.
  evidence:
  - reference: PMID:33103521
    supports: SUPPORT
    snippet: the T allele significantly increased AITD susceptibility in all genetic models involving Caucasians
    explanation: This meta-analysis of 18 studies demonstrates that PTPN22 R620W polymorphism is associated with Graves&#39; disease susceptibility.
- name: CD40
  association: Risk Factor
  notes: B-T costimulatory receptor required for germinal center reactions and TRAb
    generation.
  evidence:
  - reference: PMID:12593727
    supports: SUPPORT
    snippet: our results suggested that the CD40 gene was a new susceptibility gene for GD within certain families because it was both linked and associated with GD
    explanation: This study mapped CD40 as a susceptibility gene for Graves&#39; disease through linkage and association analyses.
- name: FCRL3
  association: Risk Factor
  notes: B cell receptor with genetic association to Graves&#39; disease susceptibility.
- name: TSHR
  association: Risk Factor
  notes: Principal autoantigen; thyrotropin receptor gene variants contribute to disease
    susceptibility in addition to being the primary target of autoantibodies.
  evidence:
  - reference: PMID:27231040
    supports: SUPPORT
    snippet: both TSHR rs179247A/G and rs12101255T/C polymorphism had significant association with GD
    explanation: This meta-analysis demonstrates that TSHR gene polymorphisms are significantly associated with Graves&#39; disease susceptibility across Asian, European, and South American populations.
environmental:
- name: Stress
  notes: Can trigger or exacerbate symptoms.
  evidence:
  - reference: PMID:11453946
    supports: SUPPORT
    snippet: Stressful life events and Graves&#39; disease revisited.
    explanation: This reference discusses the relationship between stressful life
      events and Graves&#39; disease, supporting the idea that stress can trigger or exacerbate
      symptoms.
  - reference: PMID:9972676
    supports: REFUTE
    snippet: Chronic recurrent stress due to panic disorder does not precipitate Graves&#39;
      disease.
    explanation: This study found that recurrent endogenous stress due to panic disorder
      did not precipitate Graves&#39; hyperthyroidism, suggesting that not all forms of
      stress trigger or exacerbate Graves&#39; disease.
  exposure_term:
    preferred_term: Psychological stress exposure
- name: Smoking
  notes: Increases the risk of developing and worsening Graves’ ophthalmopathy.
  evidence:
  - reference: PMID:22632372
    supports: SUPPORT
    snippet: Smoking is the most important risk factor for the occurrence/progression
      of Graves&#39; ophthalmopathy (GO), as well as for its lower/slower response to
      immunosuppression.
    explanation: The literature explicitly states that smoking is a significant risk
      factor for both the development and worsening of Graves&#39; ophthalmopathy.
  - reference: PMID:32107168
    supports: SUPPORT
    snippet: Among environmental risk factors, smoking, iodine excess, selenium and
      vitamin D deficiency, and the occupational exposure to Agent Orange have been
      associated with GD.
    explanation: The literature mentions smoking as an environmental risk factor associated
      with Graves&#39; disease.
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
diagnosis:
- name: Radioactive Iodine Uptake Test
  notes: High uptake indicates hyperthyroidism.
  evidence:
  - reference: PMID:11444164
    supports: SUPPORT
    snippet: The main uses of the radioactive iodine uptake test are to identify the
      cause of hyperthyroidism and to aid in the selection of the I-131 dose in the
      treatment of hyperthyroidism.
    explanation: The radioactive iodine uptake test is used to identify the cause
      of hyperthyroidism, which supports its use in diagnosing Graves&#39; Disease, a
      common cause of hyperthyroidism.
  - reference: PMID:10206194
    supports: SUPPORT
    snippet: Graves&#39; Disease, an autoimmune disorder, demonstrates a strong female
      prevalence; the twenty-four hour radioiodine uptake is normal or elevated.
    explanation: The radioactive iodine uptake is elevated in Graves&#39; Disease, indicating
      hyperthyroidism, which supports the statement.
  - reference: PMID:25257665
    supports: SUPPORT
    snippet: Uptake studies with (123)I or (99)Tc ((99m)Tc) provide accurate and rapid
      diagnosis but are expensive and involve radiation exposure.
    explanation: Uptake studies are used for the diagnosis of hyperthyroidism, including
      Graves&#39; Disease.
- name: Thyroid Ultrasound
  notes: Visualizes the thyroid gland and detects abnormalities.
  evidence:
  - reference: PMID:16640177
    supports: SUPPORT
    snippet: Ultrasound is a reliable examination to detect various pathologies of
      the thyroid gland and it should always be combined with a sonography of the
      surrounding soft tissues and vessels.
    explanation: The article supports the use of ultrasound in detecting various pathologies
      of the thyroid gland, which aligns with the statement that thyroid ultrasound
      visualizes the thyroid gland and detects abnormalities.
  - reference: PMID:22938934
    supports: SUPPORT
    snippet: The purpose of this paper is to review the medical literature outlining
      the important role that ultrasonography (US) can play in the diagnosis and management
      of patients with hyperthyroidism.
    explanation: The paper highlights the role of ultrasound in diagnosing and managing
      hyperthyroidism, which supports the statement regarding the use of thyroid ultrasound
      to detect abnormalities.
  - reference: PMID:30834273
    supports: SUPPORT
    snippet: The volumes determined by Q.Metrix (35.65 +/- 20.56ml) of 72 subjects
      also positively correlated with that from ultrasound (36.67 +/- 21.00ml) with
      a coefficient of 0.927 (P&lt;0.01).
    explanation: This study shows that ultrasound is used to measure thyroid volume,
      supporting the statement that thyroid ultrasound visualizes the thyroid gland
      and detects abnormalities.
  - reference: PMID:3279732
    supports: SUPPORT
    snippet: Color-flow Doppler sonography shows promise as a cost-effective, noninvasive
      technique for diagnosing Graves disease.
    explanation: The use of color-flow Doppler sonography, a form of ultrasound, in
      diagnosing Graves&#39; disease supports the statement about the utility of thyroid
      ultrasound in detecting abnormalities.
  - reference: PMID:10633216
    supports: SUPPORT
    snippet: Grey scale thyroid ultrasonography in the evaluation of patients with
      Graves&#39; disease.
    explanation: The title and context support the use of grey scale thyroid ultrasonography
      for evaluating Graves&#39; disease, aligning with the statement that thyroid ultrasound
      visualizes the thyroid gland and detects abnormalities.
treatments:
- name: Antithyroid Medications
  description: Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.
  evidence:
  - reference: PMID:17154097
    supports: SUPPORT
    snippet: Methimazole (MMI) and propylthiouracil (PTU) have been used, however,
      MMI is the preferred drug treatment.
    explanation: The reference confirms that both Methimazole and PTU are used as
      antithyroid medications to reduce thyroid hormone production in Graves&#39; disease.
  - reference: PMID:37594736
    supports: SUPPORT
    snippet: Antithyroid drugs remain a cornerstone of thyroid therapeutics.
    explanation: The reference supports the use of antithyroid medications, including
      Methimazole and PTU, in the treatment of hyperthyroidism associated with Graves&#39;
      disease.
  - reference: PMID:36740774
    supports: SUPPORT
    snippet: The thionamide anti-thyroid drugs namely carbimazole, methimazole, and
      propylthiouracil, have been the predominant therapy modality for Graves&#39; hyperthyroidism
      for over 60 years.
    explanation: The reference supports the use of Methimazole and PTU as primary
      antithyroid medications for managing Graves&#39; disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Radioactive Iodine Therapy
  description: Radioactive iodine is taken orally to destroy overactive thyroid cells.
  evidence:
  - reference: PMID:36468997
    supports: SUPPORT
    snippet: Radioactive iodine 131I is a theranostic isotope used both for diagnosis
      and therapy of benign thyroid diseases and thyroid cancer for 85 years.
    explanation: The abstract confirms that radioactive iodine is used for therapy,
      including the treatment of Graves&#39; disease, which involves destroying overactive
      thyroid cells.
  - reference: PMID:2451239
    supports: SUPPORT
    snippet: Radioactive iodine is the most frequently used and safest method of treatment
      for adults.
    explanation: This reference supports the use of radioactive iodine therapy for
      treating Graves&#39; disease by destroying overactive thyroid cells.
  - reference: PMID:1987448
    supports: SUPPORT
    snippet: In most clinical situations, a strong argument can be made for iodine-131
      therapy, which is safe and definitive, although posttreatment hypothyroidism
      and the need for lifelong thyroxine are to be expected.
    explanation: The text confirms the use of radioactive iodine therapy (iodine-131)
      for treating Graves&#39; disease, consistent with the statement.
  treatment_term:
    preferred_term: hormone modifying therapy
    term:
      id: MAXO:0000283
      label: hormone modifying therapy
- name: Thyroidectomy
  description: Surgical removal of part or all of the thyroid gland.
  evidence:
  - reference: PMID:35728139
    supports: SUPPORT
    snippet: &#39;Total thyroidectomy resulted in long-term control of thyrotoxicosis
      in all patients. There were no incidences of recurrent laryngeal nerve injury.
      One patient (1.6%) suffered permanent hypoparathyroidism. CONCLUSION: Total
      thyroidectomy is a safe and effective treatment for Graves&#39;&#39; disease.&#39;
    explanation: The study supports the statement that surgical removal of the thyroid
      gland, specifically total thyroidectomy, is used in the treatment of Graves&#39;
      disease.
  - reference: PMID:25103076
    supports: SUPPORT
    snippet: Surgery is one of the treatment choices for Graves disease.
    explanation: The study indicates that thyroidectomy is one of the treatment options
      for Graves&#39; disease, supporting the statement.
  - reference: PMID:34243871
    supports: SUPPORT
    snippet: Graves disease is an autoimmune disorder...In approximately 25% of patients,
      an inflammatory condition, Graves eye disease (GED), affects the orbital soft
      tissues.
    explanation: While this reference focuses on Graves eye disease, it indirectly
      supports the statement by discussing the broader context of Graves&#39; disease
      treatment.
  - reference: PMID:30180972
    supports: SUPPORT
    snippet: Indications for a radical treatment can arise in cases of...relapse despite
      prolonged medical treatment...Surgery is the radical method of treatment used
      in children under 5 years of age, or in cases of very large, nodular, or compressive
      goiters.
    explanation: The study discusses the use of surgery as a treatment for Graves&#39;
      disease in specific cases, supporting the statement.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Beta Blockers
  description: Used to manage cardiovascular symptoms like tachycardia and palpitations.
  evidence:
  - reference: PMID:22975536
    supports: SUPPORT
    snippet: beta-adrenergic antagonists (beta-blockers) are often used to attenuate
      the hyperadrenergic symptoms of Graves&#39; disease (GD), including palpitation.
    explanation: The study confirms that beta-blockers are used to manage cardiovascular
      symptoms like tachycardia and palpitations in Graves&#39; disease.
  - reference: PMID:36518043
    supports: SUPPORT
    snippet: Beta-blockers, mainly propranalol, are usually administered to control
      heart rate in patients with thyrotoxicosis, especially when congestive heart
      failure presents.
    explanation: The case report supports the use of beta-blockers to control heart
      rate in patients with thyrotoxicosis, which includes Graves&#39; disease.
  - reference: PMID:32402541
    supports: SUPPORT
    snippet: Tachyarrhythmias, including atrial fibrillation and tachycardia, improved
      in 85.9% of patients in the surgical group vs 66% in the medical group (P =
      .01).
    explanation: The study indicates that both surgical and medical (which includes
      beta-blockers) management improves tachyarrhythmias in Graves&#39; disease patients.
  treatment_term:
    preferred_term: beta adrenergic agent therapy
    term:
      id: MAXO:0000186
      label: beta adrenergic agent therapy
- name: Corticosteroids
  description: Used to reduce inflammation in severe ophthalmopathy.
  evidence:
  - reference: PMID:33069387
    supports: SUPPORT
    snippet: Glucocorticoids at high doses are the cornerstone in moderate-severe
      cases.
    explanation: The literature indicates that glucocorticoids (a type of corticosteroid)
      are a primary treatment for moderate-severe Graves&#39; ophthalmopathy, which supports
      their use to reduce inflammation in severe ophthalmopathy.
  - reference: PMID:29923966
    supports: SUPPORT
    snippet: Corticosteroids continue to be the primary medical therapy for TED.
    explanation: Thyroid eye disease (TED) is another term for Graves&#39; ophthalmopathy,
      and corticosteroids are noted as the primary medical therapy for this condition.
  - reference: PMID:36272013
    supports: SUPPORT
    snippet: Corticosteroids have been the first-line treatment for GO.
    explanation: Graves&#39; ophthalmopathy (GO) is treated primarily with corticosteroids,
      as indicated in the literature.
  - reference: PMID:22632369
    supports: SUPPORT
    snippet: Glucocorticoids (oral or intravenous) represent the main treatment of
      moderate-to-severe GO, the intravenous route being more effective.
    explanation: Glucocorticoids, a type of corticosteroid, are the main treatment
      for moderate-to-severe Graves&#39; ophthalmopathy, supporting their use to reduce
      inflammation.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
review_notes: Graves&#39; Disease is an autoimmune disorder that leads to hyperthyroidism,
  characterized by symptoms of an overactive thyroid such as weight loss, heat intolerance,
  and tachycardia. It can also cause specific ocular and dermatologic manifestations.
  Diagnosis involves a combination of biochemical tests with a high index of clinical
  suspicion, and treatment options vary based on severity and patient preferences.
disease_term:
  preferred_term: Graves disease
  term:
    id: MONDO:0005364
    label: Graves disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Graves_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>